Specializing in the development of drugs to treat rare diseases, BELLUS Health Inc.’s (TSE:BLU) stock has attracted much investor interest of late. The Company’s Vice President of Finance, François Desjardins, spoke with SmallCapPower at the recent Bloom Burton & Co. Healthcare Investor Conference, saying BELLUS is eagerly awaiting top-line results from a Phase III trial for its lead kidney drug. Find out more by watching our short video interview.
And, stay tuned for more SmallCapPower coverage from the Bloom Burton & Co. Healthcare Investor Conference!
